features: Bladder Cancer

EV-103 Cohort K: Promising data for first-line combination therapy of enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma

EV-103 (NCT03288545) is a multicohort study investigating the use of the antibody-drug conjugate, enfortumab vedotin, alone or in combination with…

Read More

Top 5 picks from ASCO GU 2022

Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!

Read More

First-line therapy in urothelial carcinoma: KEYNOTE-361 & DANUBE

Read More

Urothelial carcinoma updates presented at ESMO 2020: JAVELIN Bladder 100

Read More

FDA gives mitomycin gel green light for low-grade upper tract urothelial cancer

April 15th saw the Food and Drug Administration (FDA) approval of mitomycin gel (Jelmyto) for the treatment of low-grade upper…

Read More

World first in bladder cancer with FDA approval of erdafitinib

Following the release of trial data, the FDA has approved erdafitinib for the treatment of adult patients with fibroblast growth…

Read More
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals